

Mérieux Equity Partners announces two promotions to strengthen its Buyout Team

Paris/Lyon – 03 July 2024 - Mérieux Equity Partners (MxEP) is delighted to announce two strategic promotions within its Buyout team:

- **Jean-François Billet**, previously Managing Partner, has been appointed Managing Partner and Head of Buyout, a newly created role following the growth of the Buyout team. Jean-François will be responsible for structuring the development of the activity as well as leading the team. He joined Mérieux Equity Partners in 2016 and holds a PhD in Pharmacy and a degree from ESSEC Business School.
- **Theodor Wuppermann**, previously Managing Director, has been appointed Partner. Theodor joined Mérieux Equity Partners in May 2023 and has contributed to the recent investments of Mérieux Participations 4 (MP4) in LabQuality¹ and InnoSyn². He holds a Master's degree from Rotterdam School of Management and has studied International Business at Maastricht University.

Commenting on the promotions **Christine Demode, President, Mérieux Equity Partners**, said: *"Since closing our Buyout investment fund MP4 last year, Mérieux Equity Partners has continued to develop a strong pipeline of investment opportunities within healthcare. These promotions form part of our long-term strategy to expand our Buyout activities and identify the most innovative companies that will benefit from our support to fast-track their growth."*

MxEP, an AMF-accredited investment firm since 2018, has raised two funds within its buyout activity: Mérieux Participations 3 (MP3, 2018, €377m) and Mérieux Participations 4 (MP4, 2021, €568m), along with many co-investment vehicles, representing over €200m. The buyout team consists of 10 investment professionals. The strategy is to invest tickets ranging from €20m to €80m in companies with fast organic growth as well as buy-and-build platforms. MP3 and MP4 have cumulatively made 21 investments and achieved 4 exits. Recent majority investments include Innosyn, Labquality and Piercan.

¹ Labquality is a Finnish player specialized in External Quality Assessment (EQA1), Contract Research Organization (CRO) activities and Regulatory Affairs, with a strong local presence in Central and Eastern Europe. The company provides a comprehensive array of services for the healthcare, medical technology, and pharmaceutical industries. With a dynamic M&A strategy over the past three years, Labquality has initiated the development of a CRO platform, expanding its offerings to new activities and geographies.

² Leading European provider of outsourced process R&D services, located in the Netherlands. It leverages innovative and cost-efficient technologies such as biocatalysis, flow chemistry and chemocatalysis. In addition to being highly technical and innovative, InnoSyn's solutions, such as the application of flow chemistry or (bio)catalysis, are often more sustainable than conventional chemical processes, thereby contributing to a more sustainable chemical industry.

Media Contact:

CTCom (France):

Sibylle Descamps / sibylle.descamps@ct-com.com
Laure Schlagdenhauffen / laure.schlagdenhauffen@ct-com.com

MHP (UK/International):

James McFarlane / james.mcfarlane@mhpgroup.com
Matthew Taylor / matthew.taylor@mhpgroup.com

About Mérieux Equity Partners

Mérieux Equity Partners ('MxEP') is an AMF-accredited investment firm specialising in the healthcare sector. With over €1.5 billion in assets under management through two dedicated strategies: Innovation and Buyout, MxEP supports companies ranging from start-ups to established leaders.

Based in Lyon and Paris, with a strong industrial footprint, MxEP's team of healthcare specialists and investment professionals invests in European companies with significant growth and transformation potential. By providing financial and operational resources, MxEP enables businesses to achieve their goals and create value from innovative healthcare products and services which improve patient outcomes.

For more information, please visit www.merieux-partners.com